Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes

This publication has 39 references indexed in Scilit:

• Efficacy of vortioxetine on the physical symptoms of major depressive disorder
  Journal of Psychopharmacology, 2018
• Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
• Vortioxetine exerts anti‐inflammatory and immunomodulatory effects on human monocytes/macrophages
  British Journal of Pharmacology, 2017
• A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
  International Journal of Neuropsychopharmacology, 2017
• Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine
  CNS & Neurological Disorders - Drug Targets, 2017
• The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
  International Journal of Neuropsychopharmacology, 2016
• The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project
  Therapeutic Advances in Chronic Disease, 2016
• Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression
  Journal of Affective Disorders, 2012
• The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
  1992
• The MOS 36-ltem Short-Form Health Survey (SF-36)
  Medical Care, 1992